Abstract #4184

Diagnostic value of 2-hydroxyglutarate detection by 1H MR spectroscopy in patients with glioma

Francesca Branzoli^1,2, Anna Luisa Di Stefano^2,3,4, Malgorzata Marjanska⁵, Romain Valabregue^1,2, Stephane Lehericy^1,2, and Marc Sanson^2,3

¹Brain and Spine Institute (ICM), Center for Neuroimaging Research (CENIR), F-75013, Paris, France, ²INSERM U1127/CNRS UMR7225, Sorbonne Universités, UPMC Univ Paris 06, ICM, F-75013, Paris, France, ³AP-HP, GH Pitié-Salpêtrière, Service de Neurologie 2, F-75013, Paris, France, ⁴Division of Neurology, Foch Hospital, Paris, France, ⁵Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN, United States

Reliable quantification by magnetic resonance spectroscopy of the oncometabolite 2-hydroxyglutarate (2HG) has important implications in diagnosis of IDH mutation, prognosis, as well as assessment of the efficacy of anti-IDH targeted therapies. In this study, we employed two approaches for 2HG detection previously described, e.g., difference spectroscopy and optimized for 2HG detection conventional spectroscopy, in order to assess for the first time the specificity and sensitivity of the two methods, and to relate these results to the natural history and the neuroradiological status of patients with glioma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here